In This Section

Program

Please note that this meeting will take place as an in-person event in Austin and will not live-stream content for virtual participation. The meeting content will be recorded and made available as an on-demand program after the conference. Please see the registration page for details.

All presentations are scheduled to be live, in-person presentations at the date and time specified below unless noted otherwise. Program in progress.

*-Short talk from proffered abstract

Sunday, December 6

Monday, December 7

tuesday, December 8

Sunday, December 6

Opening plenary session

5-6:15 p.m.

  • 5 p.m. | Welcome from Cochairs
    Andrew Futreal, The University of Texas MD Anderson Cancer Center, Houston, Texas
  • 5:20p.m. | Keynote
    Myron Schwartz, Icahn School of Medicine Mount Sinai, New York, New York
  • 6:20 p.m. | Keynote
    Mark Yarchoan, Johns Hopkins University, Baltimore, Maryland

Opening Reception

7-9 p.m.

Monday, December 7

Breakfast

7-8 a.m.

Plenary Session 1: Molecular Pathogenesis and Risk Factors For Hepatocellular Carcinoma

8-10 a.m.

  • 8 a.m. | Overview and novel advances in understanding of the molecular pathogenesis of HCC
    Jessica Zucman-Rossi, Cordeliers Research Center at INSERM, Paris, France
  • 8:30 a.m. | Speaker to be announced
  • 9 a.m. | Matthias Heikenwälder, German Cancer Research Center, Heidelberg, Germany
  • 9:30 a.m. | Fasiha Kanwal, Baylor University, Waco, Texas

Break

10-10:30 a.m.

Plenary Session 2: Immunotherapies in Early and Intermediate HCC

10:30 a.m.-12 p.m.

  • 10:30 a.m. | Speaker to be announced
  • 11 a.m. | Neoadjuvant treatments in liver transplantation for HCC
    Vatche Agopian, UCLA, Los Angeles, California
  • 11:30 a.m. | Ed Kim, Icahn School of Medicine at Mount Sinai, New York, New York

Lunch on Own

12:15-1:30 p.m.

Plenary Session 3: Molecular and Immunotherapies in Advanced HCC

1:30-3:30 p.m.

  • 1:30 p.m. | Overview of immunotherapies in advanced HCC
    Richard S. Finn, Geffen School of Medicine at UCLA, Santa Monica, California
  • 2 p.m. | Biomarkers and mechanisms of response to immunotherapies in HCC
  • Josep M. Llovet, Icahn School of Medicine at Mount Sinai, New York, New York
  • 2:30 p.m. | Anthony El-Khoueiry, USC Norris Comprehensive Cancer Center, Los Angeles, California
  • 3 p.m. | Speaker to be announced

Break

3:30-4 p.m.

Plenary Session 4: Hot Topics in Liver Cancer (Flash Talks)

4-5 p.m.

Session Chair: Brooke E. Howitt, Stanford University, Stanford, California

  • 4 p.m. | Speaker to be announced
  • 4:15 p.m. | Artificial intelligence to predict response to systemic therapies in HCC and CCA
    Julien Calderaro-France, Assistance Publique-Hôpitaux de Paris, Paris, France
  • 4:30 p.m. | Speaker to be announced
  • 4:45 p.m. | Future of cell therapies in liver cancer
    Stephen Chan, Hong Kong University, Hong Kong, China

Poster Session & Reception

6-8 p.m.

Tuesday, December 8

Breakfast

7-8 a.m.

Plenary Session 5: Molecular Pathogenesis and Therapies in Cholangiocarcinoma

8-10 a.m.

  • 8 a.m. | Immune landscape heterogeneity across cholangiocarcinoma subtypes: Therapeutic implications
    Sumera Ilyas, Mayo Clinic, Rochester, Minnesota
  • 8:30 a.m. | Daniela Sia, Icahn School of Medicine at Mount Sinai, New York, New York
  • 9:00 a.m. | Guideline-based management of iCCA- focus onchemo and targeted therapies
    Arndt Vogel, Princess Margaret Hospital, Toronto, Canada
  • 9:30 a.m. | Robin Kate Kelly, UCSF, San Francisco, California

Break

10-10:30 a.m.

Plenary Session 6: Disparities, Pediatric Tumors and Patient’s Advocate

10:30 a.m.-12:30 p.m.

  • 10:30 a.m. | Optimizing liver cancer prevention and control in low and middle income countries and disadvantaged communities
    Louis Roberts, Mayo Clinic, Rochester, Minnesota
  • 11 a.m. | From discovery to validation: Biomarkers and precision oncology in hepatoblastoma
    Carolina Armengol, Germans Trias i Pujol Research Institute, Barcelona, Spain
  • 11:30 a.m. | Stacie Lindsey, President of Cholangiocarcinoma Foundation, Salt Lake City, Utah
  • 12 p.m. | Opportunities in prevention and surveillance of hepatocellular carcinoma
    Amit Singal, UT Southwestern Medical Center, Dallas, Texas

Closing Remarks & Departure

12:30 p.m.

  • Richard S. Finn, Geffen School of Medicine at UCLA, Santa Monica, California
  • Josep M. Llovet, Icahn School of Medicine at Mount Sinai, New York, New York
  • Jessica Zucman-Rossi, Cordeliers Research Center at INSERM, Paris, France